The translocator protein (TSPO) as a novel target for the treatment of Alzheimers disease

易位蛋白（TSPO）作为治疗阿尔茨海默病的新靶点

• 批准号: nhmrc : 632876
• 负责人: Prof Lars Ittner
• 金额: $ 41.96万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/translocator-protein-tspo-alzheimers-disease/96408
• 关键词: translocator; protein; TSPO; novel; target

Alzheimer's disease (AD) is the most prevalent dementia, characterized by progressive loss of memory. An estimated 230,000 Australians currently suffer from AD, causing a huge impact on their families and carers, as well as on national finances. The present therapies are very limited, and there is no cure. Thus, there is a need for novel treatment strategies. We have developed novel drugs that represent an innovative approach to the treatment of AD.

阿尔茨海默氏病（AD）是最普遍的痴呆症，其特征是记忆的逐渐丧失。目前，估计有23万名澳大利亚人患有广告，对其家人和护理人员以及国家财政造成了巨大影响。目前的疗法非常有限，无法治愈。因此，需要新的治疗策略。我们开发了新型药物，代表了一种创新的AD治疗方法。